Press release

New Study Recommends the Use of Masimo PVi® to Guide Fluid Administration During Major Oncosurgery with Lung Ultrasonography

IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced the findings of an abstract presented at ANESTHESIOLOGY 2021 in San Diego, in which

articleMasimo CorporationOctober 18, 20214/company/masimo-corporation/news/new-study-recommends-the-use-of-masimo-pvir-to-guide-fluid-administration-during
New Study Recommends the Use of Masimo PVi® to Guide Fluid Administration During Major Oncosurgery with Lung Ultrasonography

About this update from Masimo Corporation

[{"type":"text","content":" IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (NASDAQ: MASI) today announced the findings of an abstract presented at ANESTHESIOLOGY 2021 in San Diego, in which Drs. Anita Kulkarni and Arti Dalal at the Rajiv Gandhi Cancer Institute in New Delhi, India evaluated the use of noninvasive, continuous Masimo PVi® as part of goal-directed fluid therapy (GDFT) to guide intraoperative fluid administration during major oncosurgery in which lung ultrasonography (LUS) is used to diagnose extravascular lung water (EVLW). The researchers found that use of PVi, as a dynamic, continuous method of managing fluid administration, led to patients receiving less fluid and having fewer B-lines (a measure of EVLW), with no significant decrease in postoperative perfusion or oxygenation, compared to use of a central venous pressure (CVP)-guided fluid administration protocol.1\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005243/en/Masimo Root® with PVi® and SpHb® (Photo: Business Wire)\nNoting that conventional invasive methods of guiding fluid administration (such as CVP) during major oncosurgery may increase EVLW, which can lead to postoperative cardiorespiratory complications, the authors investigated whether use of a noninvasive, dynamic, continuous method—GDFT guided by Masimo PVi—could improve fluid management by reducing the amount of fluids administered and B-lines as measured by LUS. To evaluate PVi, they compared two groups of adult patients undergoing major oncosurgery with LUS: a group of 60 patients whose fluid administration was guided by PVi as part of GDFT and a group of 59 patients whose fluid administration was guided by CVP. Their primary outcome was detection of EVLW indicated by the total number of B-lines, and their secondary outcome was adequacy of perfusion by lactate levels at the end of surgery. The authors also measured arterial blood gas samples at baseline and the end of surgery to evaluate oxygenation.\n\nComparing the amount of fluids administered, the researchers found there were significantly fewer total crystalloids given in the PVi group (1875.8 ± 593.9 ml) compared to the CVP group (2132.6 ± 504.5 ml; p = 0.012), as well as significantly less colloid provided in the bolus (PVi group: 584 ± 358.5 ml; CVP group: 778.2 ± 242.2 ml; p = 0.001). They found ...

More updates from Masimo Corporation